More than twenty years after the first human genome was sequenced, the field is still dealing with a data problem. Sequencing a genome is faster and less expensive than it used to be. Using that data in care is still problematic.

A single genome holds about 6.4 billion data points. The hard part is making clinical sense of what is there. Clinicians often receive a narrow summary while much of the genome remains difficult to search, interpret, and use.

Simplify Genomics was created to remove that bottleneck and make the full genome more useful in everyday care.

Solving the Data Problem with Smart Genome

Over the past seven years we built Smart Genome, an automated platform that reads whole genome data and produces a clinical report with minimal manual intervention.

Since 2018, Smart Genome has curated more than 7,000 genes, interpreted millions of variants, and produced more than 10,000 clinically actionable whole genome reports across nine validated versions. We only report on well-established gene-disease associations, which is why the curation work behind the report matters.

Our genomics stack is repeatable by design. Human expertise defines the clinical logic, and Smart Genome applies that logic consistently across reporting, search, and reanalysis.

The platform was originally built by our team at Human Longevity under Craig Venter, the first person to sequence the human genome. As part of Simplify Genomics, we have continued to optimize and automate our platform.

Our Technology Stack

Smart Genome has three components.

1. Simplify Genome. Clinical whole genome reporting from our CAP-accredited, CLIA-certified lab. The content is explainable and designed for clinical use, so reporting can be faster, more reproducible, and easier for physicians to use.
2. Simplify Search. A search layer that lets a user query raw genome data and return answers in under a second, the way a search engine operates.
3. Simplify Data. A repository of more than 1.5 billion unique variants, with 1.6 million already interpreted and linked to disease and risk, that supports the report and Search.

Data Security & Privacy

We are committed to protecting the confidentiality, integrity, and availability of all data entrusted to our platform. All data is encrypted both in transit using industry-standard TLS protocols and at rest using strong encryption technologies. Our systems are designed to align with HIPAA security and privacy requirements, incorporating administrative, technical, and physical safeguards to protect sensitive health information.

Access to data is governed by the principle of least privilege, ensuring that authorized personnel have access only to the minimum information necessary to perform their responsibilities. Role-based access controls, authentication, audit logging, and ongoing security monitoring help safeguard data throughout its lifecycle.

Patients remain in control of how their data is used. We do not use patient data for research or other secondary purposes without explicit consent. When patients choose to participate, only de-identified data is shared, and no protected health information (PHI) is disclosed to third parties. Patients can update their consent preferences at any time through our consent management process, giving them ongoing control over how their data may be used.

Proven Company

Simplify began in 2016 inside Human Longevity, the genomics company founded in 2013 by Craig Venter with more than $400 million invested. In 2022, we spun out Simplify Genomics, carrying forward core technology, genomic data assets, years of expertise, and more than $90 million of prior platform development.

Since then, the business has grown almost entirely by word of mouth, from two enterprise clinical customers to fifteen with no outbound sales team.

We recently announced a collaboration with SimonMed, one of the largest imaging providers in the country, with more than 175 centers, to pair whole-body MRI with whole genome interpretation. The collaboration also gives Simplify a distribution path through SimonMed’s national footprint, rather than requiring us to build a comparable direct sales infrastructure.

We are also in active conversations with additional concierge medicine, wellness, and preventive health organizations.

What we have built:

1. An automated system that produces clinical reports from raw genomic data
2. A comprehensive whole genome screening report covering thousands of diseases
3. Search technology for near-instant analysis of genomic and clinical data
4. A database of more than 1.5 billion unique variants, with 1.6 million interpreted and linked to disease and risk

Market Demanding Change

As sequencing costs fall after years of stagnation, healthcare is moving toward whole genome sequencing as a baseline. That makes the timing right for Simplify. Our first market is concierge medicine and executive health, where practices want new ways to differentiate, support preventive care, and bring genomics into the clinical workflow. These customers are no longer asking whether genomics belongs in care. They are asking how to make it useful for physicians and patients.

Most companies in this space are built for one part of the market. Some are high-touch, centralized, and expensive. Others are lower-touch and more distributed. Moving from one model to another is hard.

Simplify was built differently. Our CAP-accredited, CLIA-certified lab gives us the clinical foundation. Smart Genome lets us automate reporting, search, and reanalysis that would otherwise require heavy manual review. That combination lets us serve clinical customers today and support larger healthcare partners as demand grows

Disciplined Business Model

As sequencing costs fall, we can price our reports at a modest markup to sequencing while still earning margin on the interpretation and reporting layer. Our goal is to grow from a model that already works.

Because Smart Genome is automated, each additional report requires relatively little incremental manual work. Annual re-reporting can become an important part of the model. Once a genome has been sequenced, updated reporting does not require sequencing again. It requires processing, reannotation, and delivery through our platform, which can be done at minimal incremental cost.

As adoption grows, the model can also add recurring revenue through Search and report subscription products. Based on the opportunities currently in front of us, our goal is to reach positive cash flow within twelve months.

(Forward-looking projections not guaranteed)

Leading the Competition

Many genomic products focus on a narrow set of findings or a limited report. Smart Genome was designed for broader clinical utility.

The report gives physicians a more comprehensive view across multiple disease areas. The search layer allows users to explore genomic and clinical data beyond the static report. The underlying database reflects eight years of interpretation work and becomes more useful as more genomes are added, and public- and licensed-annotation sources are incorporated.

Together, those pieces create a platform that is difficult to replicate quickly and designed for routine clinical use.

Future Opportunities

We are focused first on commercializing our clinical whole genome report. Beyond that, the platform creates additional opportunities through report subscriptions, broader adoption of Simplify Search, and end-to-end reporting solutions for healthcare partners.

Report subscriptions are a natural next step. A physician can order an updated analysis of a patient’s genome as new clinical information becomes available. Because the genome has already been sequenced, these updates require reanalysis and reannotation, not new sequencing, which can make them highly efficient to deliver.

Simplify Search gives physicians and healthcare partners a way to query genomic information more quickly and use the data behind the report in a more flexible way. Our data assets support these products by improving reporting, reanalysis, and Search.

Why This Round

This bridge round is intended to support commercialization while partner opportunities move forward. The funding will help us onboard partners, support clinical workflows, and add execution capacity around the team’s existing expertise without changing the company’s lean operating model.

The goal is to use targeted capital to support execution, not discovery.

Team of Industry Experts

Both founders built the original technology together at Human Longevity under Craig Venter, so they know its code and architecture firsthand.

Travis Lacey, Co-Founder and CEO, has a background in business and investment banking. Before Simplify, he built an oncology platform that sequenced tumor tissue and turned it into clinically relevant information for drug development. In 2020, the platform was acquired by NeoGenomics Laboratories.

Wayne Delport, PhD, Co-Founder and CTO, has published in leading scientific journals. He built and led bioinformatics and analytics at Human Longevity, ran the carve-out that became Simplify, and cut operating costs by more than half by optimizing storage and compute.

The Use of Funds

Simplify Genomics is raising $2 million to support commercialization of Smart Genome while maintaining a lean operating model.

The funding is expected to support:

1. Partner onboarding and implementation
2. Clinical workflow support for current and near-term agreements
3. Product development across reporting, Search, and reanalysis
4. Additional execution capacity around the team’s existing expertise
5. General working capital to support commercialization

Since spinning out of Human Longevity in 2022, Simplify has raised approximately $8 million of new capital while carrying forward core technology, genomic data assets, and more than $90 million of prior platform development. We believe that capital efficiency matters, and this round is designed to support execution rather than a large sales or hiring expansion.

Join Us

We have spent years developing the platform, validating the technology, and proving that clinical customers see value in whole genome interpretation.

The next stage is commercialization: supporting partners, expanding clinical use, and making whole genome data easier to use in clinical care.

If you would like to learn more, we would be glad to answer questions directly.

Travis and Wayne